mitazalimab   Click here for help

GtoPdb Ligand ID: 13692

Synonyms: ADC-1013 | ADC1013 | JNJ-64457107 | JNJ64457107
Compound class: Antibody
Comment: Mitazalimab (formerly JNJ-64457107, or ADC-1013) is an anti-CD40 monoclonal antibody. It binds CD40 on dendritic cells (DC) as a mechanism to activate T cell-dependent anti-tumour immunity [2]. Intratumoural administration of mitazalimab induces immunostimulant activity and initiates Fc-effector functions against tumour cells.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Irenaeus SMM, Nielsen D, Ellmark P, Yachnin J, Deronic A, Nilsson A, Norlén P, Veitonmäki N, Wennersten CS, Ullenhag GJ. (2019)
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies.
Int J Cancer, 145 (5): 1189-1199. [PMID:30664811]
2. Mangsbo SM, Broos S, Fletcher E, Veitonmäki N, Furebring C, Dahlén E, Norlén P, Lindstedt M, Tötterman TH, Ellmark P. (2015)
The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
Clin Cancer Res, 21 (5): 1115-26. [PMID:25316820]
3. Van Laethem JL, Borbath I, Prenen H, Geboes KP, Lambert A, Mitry E, Cassier PA, Blanc JF, Pilla L, Batlle JF et al.. (2024)
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.
Lancet Oncol, 25 (7): 853-864. [PMID:38834087]